Current Report Filing (8-k)
July 02 2018 - 6:17AM
Edgar (US Regulatory)
United
States
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported):
June 29, 2018
PROTAGENIC
THERAPEUTICS, INC.
(Exact
name of Company as specified in its charter)
Delaware
|
|
000-51353
|
|
06-1390025
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
149
Fifth Avenue, Suite 500, New York, NY
|
|
10010
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
212-994-8200
|
|
(Company’s
telephone number, including area code)
|
|
|
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01. Regulation FD.
In
May and June 2018, Protagenic Therapeutics, Inc. (the “Company”) began discussions with select business development
individuals representing large pharmaceutical companies with which the Company seeks to form one or more strategic corporate partnerships.
In
connection with these discussions, the Company has created a series of pitch slide decks, describing the advantages of the Company’s
lead drug compound, PT00114.
The
slide deck furnished hereto as Exhibit 99.1 is a compilation of all such pitch decks used during the months of May and June.
The
information in this Form 8-K (including the Exhibit) shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific referenced in such a filing.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
PROTAGENIC THERAPEUTICS, INC
|
|
|
|
Date:
July 2, 2018
|
By:
|
/s/
Alexander K. Arrow
|
|
Name:
|
Alexander
K. Arrow
|
|
Title:
|
Chief
Financial Officer
|